Zydus Hospital has introduced Next-Generation Sequencing (NGS), a molecular tool for detecting genetic mutations linked to ...

Zydus Lifesciences has received final approval from the United States Food and Drug Administration (USFDA) to manufacture Apalutamide Tablets, 60 mg (Erleada Tablets, 60 mg).

Zydus Lifesciences Ltd has received USFDA approval to manufacture a generic version of Apalutamide tablets for prostate cancer treatment. The 60 mg tablets will be produced in Ahmedabad, addressing a ...

The company got the nod to manufacture and market apalutamide tablets, 60 mg, the generic equivalent of Erleada tablets, 60 mg. Shares of Zydus Lifesciences Ltd ended at ₹901.15, up by ₹7.85, or 0.88% ...

The uptick in the Zydus Life shares came after the company received final approval from the USFDA to manufacture Eluxadoline ...

Sun Pharma and Zydus Pharmaceuticals are recalling products in the US market due to manufacturing issues, according to the ...

India's Zydus Lifesciences said on Tuesday it will acquire an 85.6% stake in France's Amplitude Surgical for 256.8 million ...

Zydus Lifesciences shares rose nearly 2% to Rs 899.40 after receiving USFDA approval to manufacture Eluxadoline Tablets (75 ...

India still relies largely on imported devices and implants, when it comes to MedTech. This offers us a great opportunity to ...

Sun Pharma and Zydus Pharmaceuticals are recalling significant quantities of their products in the US due to manufacturing ...

Eluxadoline tablets will be produced at Zydus Lifesciences Ltd (SEZ) in Ahmedabad, the company said in an exchange filing.

Inspection occurred from March 10, 2025 to March 14, 2025 and ended with no observations with full compliance.